



Takeda Information

Corrections with respect to the Financial Statements for the Three Months Period Ended June 30, 2016

Osaka, Japan, August 1, 2016 - Takeda Pharmaceutical Company Limited (“Takeda”) announced today some corrections in the consolidated financial statements (IFRS) for the three months period ended June 30, 2016, which was filed on July 29, 2016. Corrections are double underlined as below.

Attachment

1. Qualitative Information for the Three Months Period Ended June 30, 2016
 - (1) Business Performance
 - (i) Consolidated Financial Results (April 1 to June 30, 2016)

P.4 <Incorrect>

- The consumer healthcare business and other businesses benefited from favorable sales of ALINAMIN tablets, resulting in revenue of 40.0 billion JPY, an increase of 1.5 billion JPY (+3.8%) compared to the same period of the previous year.

P.4 <Correct>

- The consumer healthcare business and other businesses benefited from favorable sales of ALINAMIN drinks, resulting in revenue of 40.0 billion JPY, an increase of 1.5 billion JPY (+3.8%) compared to the same period of the previous year.

P.6 <Incorrect>

- Revenue in the Consumer Healthcare Business was 20.4 billion JPY, an increase of 1.0 billion JPY (+4.9%) compared to the same period of the previous year, mainly due to the increase in sales of ALINAMIN tablets (vitamin-containing products). Operating profit was 7.4 billion JPY, a decrease of 0.2 billion JPY (-3.3%).

P.6 <Correct>

- Revenue in the Consumer Healthcare Business was 20.4 billion JPY, an increase of 1.0 billion JPY (+4.9%) compared to the same period of the previous year, mainly due to the increase in sales of ALINAMIN drinks (vitamin-containing products). Operating profit was 7.4 billion JPY, a decrease of 0.2 billion JPY (-3.3%).

###